Intra-cellular Therapies, INC Form 4 insider transactions

Lawrence J. Hineline, SVP of Finance and CFO of Intra-Cellular Therapies, Inc., reports the acquisition of 26,227 restricted stock units on March 1, 2024.

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, Inc., was granted 26,227 restricted stock units on March 1, 2024.

Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., was granted 26,227 restricted stock units on March 1, 2024.

Sharon Mates, Chairman, President, and CEO of Intra-Cellular Therapies, Inc., was granted 104,909 restricted stock units on March 1, 2024, according to a Form 4 filing.

Director Robert L. Van Nostrand exercised stock options and sold shares of Intra-Cellular Therapies, Inc. on February 27, 2024.

Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies, Inc., reported the sale of common stock and the conversion of restricted stock units, with sales executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence J. Hineline, CFO of Intra-Cellular Therapies, Inc., reports the sale of common stock and conversion of restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Mates, CEO of Intra-Cellular Therapies, sold shares of common stock to cover tax liabilities arising from the vesting of restricted stock units, as part of a pre-arranged Rule 10b5-1 trading plan.

Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., reports the sale of common stock and conversion of restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, sold shares of ITCI common stock on February 26, 2024, to cover tax liabilities arising from vesting restricted stock units, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Joel S. Marcus exercised stock options and sold shares of Intra-Cellular Therapies on February 26, 2024.